<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088292</url>
  </required_header>
  <id_info>
    <org_study_id>STRATIFY-1</org_study_id>
    <nct_id>NCT04088292</nct_id>
  </id_info>
  <brief_title>Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism</brief_title>
  <acronym>STRATIFY</acronym>
  <official_title>Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hillerod Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label clinical randomized trial comparing three strategies for managing acute
      intermediate-high risk pulmonary embolism
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial acronym: STRATIFY Background: Intermediate-high risk pulmonary embolism (PE) is
      associated with a significant risk of death or hemodynamic deterioration. The optimal
      treatment strategy should balance efficacy in reducing thrombus burden and hemodynamic
      compromise with risk of complications, in particular bleeding. Previous studies have
      investigated conventional high-dose, short term thrombolysis by (rtPA), finding a reduction
      in risk hemodynamic deterioration, but no reduction in mortality and a substantial increase
      in significant bleeding complications.

      Catheter based techniques and low dose thrombolysis may offer lower risk of complication with
      reasonable efficacy. Such studies have not been performed in RCTs with a reasonable sample
      size, and no study have compared low dose intravenous thrombolysis and catheter based
      techniques.

      The current trial addresses this paucity of data by randomizing patients to one of three
      treatment modalities:

      Intervention: 1:1:1 randomization, stratified for site to

        -  UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA,
           Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight
           heparin (LMWH) within 12 hours of randomization

        -  Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or
           low molecular weight heparin (LMWH).

        -  UFH or low molecular weight heparin (LMWH) only (with option for conventional
           thrombolysis according to local protocols for hemodynamic deterioration) Design:
           Regional collaborative, randomized trial with 1:1:1 allocation of 210 patients with
           acute intermediate-high risk PE with no absolute contraindications to thrombolysis
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial with 1:1:1 allocation to treatment strata</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Primary endpoint will be assessed by assessor blinded to the intervention</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Miller score comparing low dose thrombolysis and heparin alone groups</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Reduction in Miller Score and on follow-up (48-96 h) CT pulmonary Angiography comparing low-dose rtPA (±USAT) to UFH/LMWH group (p&lt;0.01, N=210)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction i Miller score comparing low dose thrombolysis by iv and by USATgroups</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>reduction in Miller Score and on follow-up (48-96 h) CT pulmonary Angiography comparing low-dose rtPA by USAT to iv, p&lt;0.04, N=140)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of bleeding complications</measure>
    <time_frame>Until hospital discharge, on average 1 week</time_frame>
    <description>Bleeding complications (major and minor bleeding complication according the TIMI classification)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay of index admission</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Duration of index admission, including hospital based rehabilitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea index by visual analogue scale</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Dyspnea index (Visual analog scale) after 48-96 h and after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen supplement (FiO2)</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>FiO2 (in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>End of study, expected to be 2 years</time_frame>
    <description>Mortality in the three groups (log-rank), and hazard ratio in multivariable analysis using the UFH/LMWH as reference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in D-dimer values</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Reduction in D-dimer from baseline to 48-96h post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Pulmonary Hypertension</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Incidence of TR gradient &gt; 40 mmHg at 3 months follow-up echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in troponin levels</measure>
    <time_frame>at 48 to 96 hours post randomization</time_frame>
    <description>Relative reduction in TnI/T from baseline to 48-96 h post intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in NT-pro-BNP levels</measure>
    <time_frame>3 months follow-up</time_frame>
    <description>Reduction in NT-pro-BNP at 48-96 hours and 3 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose thrombolysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heparin alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase 20 Mg Powder for Solution for Injection Vial</intervention_name>
    <description>Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device</description>
    <arm_group_label>Low dose thrombolysis</arm_group_label>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultrasound assisted Thrombolysis</intervention_name>
    <description>Ultrasound assisted thrombolysis (USAT)</description>
    <arm_group_label>USAT + low dose thrombolysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Informed consent for trial participation

          3. Intermediate high-risk PE according to ESC criteria

          4. Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography

          5. 14 days of symptoms or less

        Exclusion Criteria:

          1. Altered mental state (GCS &lt; 14)

          2. No qualifying CT angiography performed (&gt; 24 hour since CT angiography)

          3. Females of child bearing potential, unless negative HCG test is present

          4. Thrombolysis for PE within 14 days of randomization

          5. Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)

          6. Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC
             allowed)

          7. Comorbidity making 6 months survival unlikely

          8. Absolute contraindications for thrombolysis

               1. Hemorrhagic stroke or stroke of unknown origin at any time

               2. Ischemic stroke in the preceding 6 months

               3. Central nervous system damage or neoplasms

               4. Recent major trauma/surgery/head injury in the preceding 3 weeks

               5. Gastrointestinal bleeding within the last month

               6. Known bleeding risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jesper Kjærgaard, MD PhD DMSc</last_name>
    <phone>+45 35450969</phone>
    <email>jesper.kjaergaard.05@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lia Bang, MD PhD</last_name>
    <phone>+45 35453545</phone>
    <email>lia.evi.bang@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital Bispebjerg Hospital</name>
      <address>
        <city>Bispebjerg</city>
        <zip>DK2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Egstrup, MD PhD</last_name>
      <phone>+45 38 63 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia E Bang, MD PhD</last_name>
      <phone>+45 3545 3545</phone>
      <email>lia.evi.bang@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Herlev Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Søren Fanø, MD PhD</last_name>
      <phone>+45 38 68 38 68</phone>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Jesper Kjaergaard</investigator_full_name>
    <investigator_title>Sponsor, Primary investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Main trial database</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

